Watch Live

Tweet TWEET

XenoPort to Release Third Quarter Financial Results on November 7

  XenoPort to Release Third Quarter Financial Results on November 7

Business Wire

SANTA CLARA, Calif. -- October 30, 2013

XenoPort, Inc. (Nasdaq: XNPT) announced today that it will release its third
quarter financial results on November 7, 2013 at approximately 4:30 p.m.
Eastern Time. The company will host a conference call at 5:00 p.m. Eastern
Time that same day to provide a summary of its financial results, general
business updates and a review of additional clinical data and program
developments for XP23829, XenoPort’s novel fumaric acid ester product
candidate.

To access the conference call via the Internet, go to www.XenoPort.com. Please
join the call at least 15 minutes prior to the start to ensure time for any
software downloads that may be required.

To access the live conference call via phone, dial 1-888-275-3514.
International callers may access the live call by dialing 706-679-1417. The
reference number to enter the call is 77314561.

A replay of the conference call will be available for one week following the
event and may be accessed after 8:00 p.m. Eastern Time that same day via the
Internet, at www.XenoPort.com, or via phone at 1-855-859-2056 for domestic
callers, or 404-537-3406 for international callers. The reference number to
enter the replay of the call is 77314561.

About XenoPort

XenoPort, Inc. is a biopharmaceutical company focused on developing and
commercializing a portfolio of internally discovered product candidates for
the potential treatment of neurological disorders. XenoPort is currently
commercializing HORIZANT^® (gabapentin enacarbil) Extended-Release Tablets in
the United States and developing its novel fumaric acid ester product
candidate, XP23829, as a potential treatment for relapsing-remitting multiple
sclerosis and/or psoriasis. REGNITE^® (gabapentin enacarbil) Extended-Release
Tablets is being marketed in Japan by Astellas Pharma Inc. XenoPort's pipeline
of product candidates includes potential treatments for patients with
spasticity related to spinal cord injury and Parkinson's disease. To learn
more about XenoPort, please visit the Website at www.XenoPort.com.

HORIZANT, REGNITE and XENOPORT are registered trademarks of XenoPort, Inc.

XNPT2F

Contact:

XenoPort, Inc.
Jackie Cossmon, 408-616-7220
ir@XenoPort.com